title: [Reduction of medical resources utilization by influenza vaccination for hospitalized elderly patients].
abstract: In order to evaluate the economic efficacy of influenza vaccination for the elderly inpatients, we have investigated the health insurance fee of elderly inpatients in Japan. It was revealed that the health insurance fee varied by patients largely, ranging from 7,000 yen to 90,000 yen. Primary reason of this variation was due to the existence of the same effective drugs with variant prices and there were no rules concerning the period of drug medication. Thus, it was found that it would be improper to use the medication fee as a measure in evaluating the effects of influenza vaccinations. In this study, we used the length of days of testing and medication such as oral antibiotics, blood cell count, etc. as a measure to evaluate the effect of influenza vaccination. We compared these measures among elderly hospitalized patients with influenza vaccination or without influenza vaccination by ADL. Mean length of days of oral antibiotics was 2.64 (+/- 6.40) days for those with vaccination, and 3.92 (+/- 7.31) days for those without vaccination. Mean length of days of injection antibiotics was 2.52 (+/- 5.53) days for those with vaccination, and 8.82 (+/- 15.1) days for those without vaccination. Mean length of days of cells blood counter was 2.63 (+/- 2.22) days for those with vaccination, and 4.44 (+/- 3.20) days for those without vaccination. Mean length of days of chest X-ray was 1.30 (+/- 2.07) days for those with vaccination, and 2.56 (+/- 3.49) days for those without vaccination. These results suggest that influenza vaccination reduces medical utilization of resources. It was also revealed that influenza vaccination is most effective when elderly patients who are bed-bound are vaccinated.
authors.affiliation: Department of Health Services Management and Policy, Graduate School of Medicine, Kyushu University.
authors.forename: Y
authors.initials: Y
authors.lastname: Hara
authors.forename: H
authors.initials: H
authors.lastname: Ikematsu
authors.forename: A
authors.initials: A
authors.lastname: Nabeshima
authors.forename: A
authors.initials: A
authors.lastname: Hagiwara
authors.forename: K
authors.initials: K
authors.lastname: Nobutomo
authors.forename: S
authors.initials: S
authors.lastname: Kashiwagi
mesh_terms: D000368:Aged; D003362:Cost-Benefit Analysis; D005260:Female; D006760:Hospitalization; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000628:therapy*; D008297:Male; D009313:National Health Programs / Q000191:economics; D014611:Vaccination / Q000191:economics*
chemical_list: D007252:Influenza Vaccines